His primary areas of investigation include Internal medicine, Oncology, Surgery, Phases of clinical research and Crizotinib. Internal medicine and Gastroenterology are frequently intertwined in his study. His Oncology research incorporates elements of Adenocarcinoma, Tolerability and Regimen, Pathology.
His Surgery research includes themes of Neoadjuvant therapy, Cancer and Oxaliplatin, FOLFIRINOX. His Phases of clinical research research includes elements of Prospective cohort study and Neutropenia. His Crizotinib study integrates concerns from other disciplines, such as Anaplastic lymphoma kinase and Gene rearrangement.
Internal medicine, Oncology, Surgery, Cancer and Colorectal cancer are his primary areas of study. Internal medicine is often connected to Gastroenterology in his work. He has researched Oncology in several fields, including Pathology, Radiation therapy and Adenocarcinoma.
His work in Surgery tackles topics such as Irinotecan which are related to areas like Oxaliplatin. His studies in Colorectal cancer integrate themes in fields like Bevacizumab, Fluorouracil and Metastasis. The study incorporates disciplines such as Cancer research, non-small cell lung cancer, Anaplastic lymphoma kinase, Exon and ROS1 in addition to Crizotinib.
Jeffrey W. Clark mainly focuses on Internal medicine, Oncology, Colorectal cancer, Cancer and Cancer research. Many of his studies involve connections with topics such as Gastroenterology and Internal medicine. In his study, Perioperative is strongly linked to Circulating tumor DNA, which falls under the umbrella field of Oncology.
His Colorectal cancer research integrates issues from Locally advanced, Primary tumor and Nuclear medicine. Jeffrey W. Clark works mostly in the field of Cancer, limiting it down to topics relating to Hazard ratio and, in certain cases, Odds ratio. Nivolumab and Ipilimumab is closely connected to Phases of clinical research in his research, which is encompassed under the umbrella topic of Cancer research.
The scientist’s investigation covers issues in Internal medicine, Oncology, Crizotinib, Gastroenterology and Cancer research. His studies in Hepatocellular carcinoma, Carcinoma, Oxaliplatin, Proportional hazards model and Hazard ratio are all subfields of Internal medicine research. His Oncology research is multidisciplinary, incorporating elements of Colorectal cancer, Primary tumor, Targeted therapy and Mutational analysis.
His research in Crizotinib intersects with topics in ROS1, Chemotherapy and Exon. Jeffrey W. Clark focuses mostly in the field of Gastroenterology, narrowing it down to topics relating to Radiation therapy and, in certain cases, Liver cancer and CD8. His Cancer research study combines topics from a wide range of disciplines, such as Cancer, Nivolumab, Ipilimumab, Immunotherapy and Clone.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Eunice L. Kwak;Yung-Jue Bang;D. Ross Camidge;Alice T. Shaw.
The New England Journal of Medicine (2010)
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
Christopher G Willett;Yves Boucher;Emmanuelle di Tomaso;Dan G Duda.
Nature Medicine (2004)
ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers
Kristin Bergethon;Alice T. Shaw;Sai Hong Ignatius Ou;Ryohei Katayama.
Journal of Clinical Oncology (2012)
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Alice T. Shaw;Sai Hong I. Ou;Yung Jue Bang;D. Ross Camidge.
The New England Journal of Medicine (2014)
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
D. Ross Camidge;Yung Jue Bang;Eunice L. Kwak;A. John Iafrate.
Lancet Oncology (2012)
Lessons from phase III clinical trials on anti-VEGF therapy for cancer
Rakesh K Jain;Dan G Duda;Jeffrey W Clark;Jay S Loeffler.
Nature Reviews Clinical Oncology (2006)
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.
Alice T. Shaw;Beow Y. Yeap;Benjamin J. Solomon;Gregory J. Riely.
Lancet Oncology (2011)
Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
James E. Butrynski;David R. D’Adamo;Jason L. Hornick;Paola Dal Cin.
The New England Journal of Medicine (2010)
Quality of informed consent in cancer clinical trials: a cross-sectional survey
Steven Joffe;Steven Joffe;E Francis Cook;Paul D Cleary;Jeffrey W Clark.
The Lancet (2001)
Phase II Study of Temozolomide and Thalidomide in Patients With Metastatic Neuroendocrine Tumors
Matthew H. Kulke;Keith Stuart;Peter C. Enzinger;David P. Ryan.
Journal of Clinical Oncology (2006)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: